雷莫西尤单抗，另一种用于二线治疗转移性结直肠癌的抗血管生成药物——其对临床实践的影响。
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.
作者信息
Goel Gaurav, Sun Weijing
机构信息
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA, 15232, USA.
出版信息
J Hematol Oncol. 2015 Jul 28;8:92. doi: 10.1186/s13045-015-0183-8.
Abstract
The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.
摘要
美国食品药品监督管理局（FDA）近期批准了雷莫西尤单抗（RAISE试验），这为我们现有的抗血管生成抑制剂（贝伐单抗和Ziv-阿柏西普）药库增添了第三种药物，用于转移性结直肠癌的二线治疗，这可能会对当前的临床实践产生一些影响。
相似文献
1
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.雷莫西尤单抗，另一种用于二线治疗转移性结直肠癌的抗血管生成药物——其对临床实践的影响。
J Hematol Oncol. 2015 Jul 28;8:92. doi: 10.1186/s13045-015-0183-8.
2
[New molecular targeting drugs for metastatic colorectal cancer].[转移性结直肠癌的新型分子靶向药物]
Nihon Rinsho. 2014 Jan;72(1):120-6.
3
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?转移性结直肠癌二线抗血管生成治疗：简单还是复杂？
Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12.
4
Economics of ramucirumab for metastatic colorectal cancer.雷莫西尤单抗用于转移性结直肠癌的经济学分析
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):733-745. doi: 10.1080/14737167.2016.1259070.
5
Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.贝伐单抗联合氟嘧啶类方案用于转移性结直肠癌一线治疗的安全性
Clin Colorectal Cancer. 2006 Sep;6(3):189-91. doi: 10.1016/S1533-0028(11)70281-X.
6
Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.雷莫西尤单抗治疗结直肠癌的临床药代动力学和药效学
Expert Opin Drug Metab Toxicol. 2016;12(4):449-56. doi: 10.1517/17425255.2016.1156084. Epub 2016 Mar 10.
7
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.西妥昔单抗用于一线转移性结直肠癌及间歇性姑息化疗：COIN试验综述
Expert Rev Anticancer Ther. 2008 Aug;8(8):1237-45. doi: 10.1586/14737140.8.8.1237.
8
The safety of ramucirumab for the treatment of colorectal cancer.雷莫芦单抗治疗结直肠癌的安全性。
Expert Opin Drug Saf. 2018 Sep;17(9):945-951. doi: 10.1080/14740338.2018.1506762. Epub 2018 Aug 16.
9
Targeted therapy for metastatic colorectal cancer: role of aflibercept.转移性结直肠癌的靶向治疗：阿柏西普的作用。
Clin Colorectal Cancer. 2013 Jun;12(2):73-85. doi: 10.1016/j.clcc.2012.08.001. Epub 2012 Oct 24.
10
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.雷莫西尤单抗用于治疗胃癌、结直肠癌和其他胃肠道恶性肿瘤。
Expert Rev Clin Pharmacol. 2016 Jul;9(7):877-85. doi: 10.1080/17512433.2016.1182861. Epub 2016 Jun 2.
引用本文的文献
1
studies, synthesis, characterization and studies of levosulpiride derivatives.左舒必利衍生物的研究、合成、表征及相关研究
Future Med Chem. 2024;16(23):2459-2473. doi: 10.1080/17568919.2024.2408213. Epub 2024 Oct 15.
2
Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance.靶向癌症干细胞作为致癌和治疗抵抗的关键驱动因素。
Int J Mol Sci. 2023 Jan 16;24(2):1786. doi: 10.3390/ijms24021786.
3
Precision treatment in colorectal cancer: Now and the future.结直肠癌的精准治疗：现状与未来。
JGH Open. 2019 Feb 8;3(5):361-369. doi: 10.1002/jgh3.12153. eCollection 2019 Oct.
4
Targeting Receptor Kinases in Colorectal Cancer.靶向结直肠癌中的受体激酶
Cancers (Basel). 2019 Mar 27;11(4):433. doi: 10.3390/cancers11040433.
5
Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1).Vegfr2（Flk1）杂合子小鼠的肿瘤生长和血管生成受损。
Sci Rep. 2018 Oct 3;8(1):14724. doi: 10.1038/s41598-018-33037-2.
6
Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.靶向VEGFR药物治疗晚期或转移性胃癌的疗效与安全性：一项系统评价和荟萃分析
Oncotarget. 2017 Dec 19;9(8):8120-8132. doi: 10.18632/oncotarget.23429. eCollection 2018 Jan 30.
7
Involvement of breast cancer stem cells in tumor angiogenesis.乳腺癌干细胞在肿瘤血管生成中的作用。
Oncol Lett. 2017 Dec;14(6):8150-8155. doi: 10.3892/ol.2017.7238. Epub 2017 Oct 20.
8
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.现代免疫疗法在胃肠道恶性肿瘤中的作用：当前临床进展综述
J Hematol Oncol. 2017 Apr 24;10(1):86. doi: 10.1186/s13045-017-0454-7.
9
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.呋喹替尼在既往接受过治疗的转移性结直肠癌患者中的安全性和有效性：一项Ib期研究和一项随机双盲II期研究。
J Hematol Oncol. 2017 Jan 19;10(1):22. doi: 10.1186/s13045-016-0384-9.
10
Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis.血管生成抑制剂在晚期胃癌中的疗效与安全性：一项系统评价与荟萃分析
J Hematol Oncol. 2016 Oct 18;9(1):111. doi: 10.1186/s13045-016-0340-8.
本文引用的文献
1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.雷莫芦单抗联合 FOLFIRI 二线治疗用于贝伐珠单抗、奥沙利铂和氟嘧啶一线治疗后进展的转移性结直肠癌患者：一项随机、双盲、多中心、III 期研究（RAISE）。
Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
2
Strategies for modern biomarker and drug development in oncology.肿瘤学中现代生物标志物与药物开发的策略
J Hematol Oncol. 2014 Oct 3;7:70. doi: 10.1186/s13045-014-0070-8.
3
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.在六项评估贝伐珠单抗联合标准治疗的随机 III 期临床试验中，血管内皮生长因子通路基因的遗传变异性。
Angiogenesis. 2014 Oct;17(4):909-20. doi: 10.1007/s10456-014-9438-1. Epub 2014 Jul 11.
4
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Fcγ 受体多态性在癌症中对单克隆抗体反应的作用的批判性评价。
J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1.
5
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.贝伐珠单抗治疗转移性结直肠癌（ML18147）一线进展后的延续治疗：一项随机 3 期临床试验
Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.
6
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.血管内皮生长因子剪接异构体与贝伐单抗治疗转移性结直肠癌患者无进展生存期的关系。
Clin Cancer Res. 2012 Nov 15;18(22):6384-91. doi: 10.1158/1078-0432.CCR-12-2223. Epub 2012 Oct 25.
7
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.在既往接受基于奥沙利铂方案治疗的转移性结直肠癌患者中，阿柏西普联合氟尿嘧啶、亚叶酸钙和伊立替康可改善生存，这在一项 III 期随机试验中得到证实。
J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4.
8
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.鉴定血清血管生成素-2 作为贝伐珠单抗治疗的结直肠癌患者临床结局的生物标志物。
Br J Cancer. 2010 Oct 26;103(9):1407-14. doi: 10.1038/sj.bjc.6605925. Epub 2010 Oct 5.
9
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗：抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
10
Vascular endothelial growth factor as a target for anticancer therapy.血管内皮生长因子作为抗癌治疗的靶点。
Oncologist. 2004;9 Suppl 1:2-10. doi: 10.1634/theoncologist.9-suppl_1-2.
Zotero 插件